381 completed, 47 terminated, 40 recruiting, 19 withdrawn. 532 Phase 3, 71 Phase 2.
Follow Depressive Disorder: new trials by email Literature Review of Depressive Disorder trials Research Report on Depressive Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial Neuronavigated robotic-enabled TMS, NRX-101, Sham TMS - Treatment Resistant Depression, Treatment Resistant Depression (TRD) | Phase 2 / Phase 3 | Recruiting | NeuroRx, Inc. | 240 | 2026-12-01 | 2026-10-21 |
| A Study of Lumateperone Versus Placebo in Participants With Major Depressive Disorder Lumateperone, Placebo - Depressive Disorder, Major | Phase 3 | Not yet recruiting | Intra-Cellular Therapies, Inc. | 585 | 2026-10-20 | 2026-08-31 |
| Study of Lurasidone as Adjunctive Treatment in Patients With Major Depressive Disorder With Inadequate Response to Antidepressant Monotherapy Lurasidone, Placebo, Background Antidepressant Therapy - Major Depressive Disorder (MDD), Major Depressive Disorder With Psychotic Features | Phase 3 | Not yet recruiting | Bukwang Pharmaceutical | 364 | 2026-09-28 | 2026-09-16 |
| Brexanolone Lifting Outcomes Of Moms LPCN 1154A, Placebo - Depression, Postpartum, Postpartum Depression (PPD) | Phase 3 | Recruiting | Lipocine Inc. | 120 | 2026-09-01 | 2026-09-16 |
| Behavioural Activation Therapy and Ketamine for Treatment-Resistant Depression Ketamine (0.5 mg/kg), Behavioural Activation Therapy - Treatment Resistant Depression, Major Depressive Disorder (MDD) | Phase 2 / Phase 3 | Not yet recruiting | The Royal's Institute of Mental Health Research | 60 | 2026-09-01 | 2026-09-03 |
| Lumateperone for Late-Life Depression Lumateperone, Placebo - Treatment Resistant Depression (TRD), Late Life Depression (LLD) | Phase 3 | Recruiting | Eric Lenze | 100 | 2026-09-01 | 2026-09-16 |
| Study of rTMS in Maintenance in Treatment Resistant Depression Transcranial Magnetic Stimulation, quetiapine - Treatment Resistant Depression (TRD) | Phase 3 | Not yet recruiting | All India Institute of Medical Sciences, Bhubaneswar | 68 | 2026-08-30 | 2026-08-12 |
| A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder Brenipatide, Placebo - Depressive Disorder, Major | Phase 3 | Recruiting | Eli Lilly and Company | 1000 | 2026-08-14 | 2026-10-07 |
| Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression Psilocybin - Major Depression | Phase 3 | Recruiting | VA Office of Research and Development | 240 | 2026-08-03 | 2026-10-23 |
| A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression Esketamine 56 mg, Esketamine 84 mg, Placebo - Depressive Disorder, Treatment-Resistant | Phase 3 | Recruiting | Janssen Research & Development, LLC | 348 | 2026-07-23 | 2026-09-25 |
| A Study of MI078 for Postpartum Depression MI078 capsule, Placebo of MI078 capsules - Postpartum Depression (PPD) | Phase 3 | Recruiting | Nanjing Minova Pharmaceutical Co., Ltd. | 200 | 2026-07-10 | 2026-07-23 |
| Compare the Efficacy and Safety of KH607 Tablets Versus Vortioxetine Hydrobromide Tablets in Adult Patients With Major Depressive Disorder KH607 tablets, Vortioxetine Hydrobromide Tablets, Part B: KH607 - Major Depressive Disorder (MDD) | Phase 3 | Not yet recruiting | Chengdu Kanghong Pharmaceutical Group Co., Ltd. | 326 | 2026-07-01 | 2026-08-03 |
| A Study of KH607 as Monotherpy in Adults Participants With Major Depressive Disorder KH607 tablets, placebo - Major Depressive Disorder (MDD) | Phase 3 | Not yet recruiting | Chengdu Kanghong Pharmaceutical Group Co., Ltd. | 232 | 2026-07-01 | 2026-08-03 |
| Dehydroepiandrosterone (DHEA) as Augmentation of Standard Antidepressants in Treatment-resistant Depression. Dehydroepiandrosterone (DHEA), Placebo - Treatment Resistant Depression (TRD) | Phase 3 | Recruiting | Charite University, Berlin, Germany | 320 | 2026-06-22 | 2026-09-28 |
| A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend) Placebo, DT120 - Major Depressive Disorder | Phase 3 | Recruiting | Definium Therapeutics US, Inc. | 165 | 2026-05-10 | 2026-10-23 |
| InTRavenous kEtAmine and immerSive virtUal Reality to Treat dEpression Ketamine, Oculus VR headset - Treatment Resistant Depression | Phase 3 | Recruiting | Sunnybrook Health Sciences Centre | 31 | 2026-05-03 | 2026-10-23 |
| A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder Seltorexant, Placebo - Depressive Disorder, Major | Phase 3 | Recruiting | Janssen Research & Development, LLC | 600 | 2026-04-30 | 2026-10-01 |
| Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Major Depressive Disorder Psilocybin, Structured Integrated Reframing Therapy (SIRT), Selective Serotonin Reuptake Inhibitor (SSRI) - Major Depressive Disorder, Post-Traumatic Stress Disorder (PTSD) | Phase 3 | Recruiting | Khyber Medical University Peshawar | 60 | 2026-04-01 | 2026-07-14 |
| REVEAL Study - Diagnostic Testing for PTSD Using the Senseye Diagnostic Tool Senseye Diagnostic Tool (DT), Clinician Administered PTSD Scale for DSM-5, Revised Version - PTSD - Post Traumatic Stress Disorder | Phase 3 | Recruiting | Senseye, Inc. | 1900 | 2026-02-23 | 2026-04-29 |
| Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol Solriamfetol 150 MG, Placebo - Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms | Phase 3 | Recruiting | Axsome Therapeutics, Inc. | 508 | 2026-02-23 | 2026-10-13 |
Showing 20 of 532. Sign in to see all of them.
Depressive Disorder, Major (437) · Depression (215) · Depressive Disorder, Treatment-Resistant (46) · Depression, Postpartum (21) · Bipolar Disorder (20) · Mood Disorders (15) · Mental Disorders (13) · Psychotic Disorders (13) · Anxiety Disorders (12) · Sleep Initiation and Maintenance Disorders (9) · Suicidal Ideation (7) · Dysthymic Disorder (5) · Inflammation (5) · Premenstrual Dysphoric Disorder (5)
Mental Disorders (519) · Mood Disorders (517) · Behavior (222) · Behavioral Symptoms (219) · Pathological Conditions, Signs and Symptoms (31) · Nervous System Diseases (27) · Urogenital Diseases (26) · Female Urogenital Diseases and Pregnancy Complications (23) · Bipolar and Related Disorders (20) · Pregnancy Complications (20) · Puerperal Disorders (20) · Pathologic Processes (19) · Schizophrenia Spectrum and Other Psychotic Disorders (16) · Signs and Symptoms (15)
Escitalopram (44) · Vortioxetine (35) · Duloxetine Hydrochloride (32) · Fluoxetine (23) · Sertraline (22) · Ketamine (21) · Antidepressive Agents (15) · Aripiprazole (15) · brexpiprazole (15) · Paroxetine (13) · Esketamine (12) · Quetiapine Fumarate (11) · Venlafaxine Hydrochloride (11) · Desvenlafaxine Succinate (10) · GLYX-13 peptide (10)
Eli Lilly and Company (24) · Janssen Research & Development, LLC (21) · H. Lundbeck A/S (20) · Sanofi (19) · Forest Laboratories (18) · Otsuka Pharmaceutical Development & Commercialization, Inc. (18) · Wyeth is now a wholly owned subsidiary of Pfizer (18) · AstraZeneca (14) · Takeda (14) · GlaxoSmithKline (12) · Naurex, Inc, an affiliate of Allergan plc (10) · Merck Sharp & Dohme LLC (9) · Pfizer (9) · Biogen (8) · Alkermes, Inc. (7)
United States (310) · Canada (92) · Germany (63) · Poland (59) · France (45) · Spain (42) · Bulgaria (41) · Finland (38) · Slovakia (36) · Mexico (34) · Czechia (33) · Japan (32) · Hungary (31) · Russia (30) · Sweden (30)
Jenna Hoogerheyde (9) · Sanjeev Pathak, MD (6) · Carl Gommoll, MS (5)
PMID 25758058, PMID 24816198, PMID 26644956, PMID 26709542, PMID 29140227, PMID 34183490, PMID 24067192, PMID 24175720, PMID 26474010, PMID 24571916, PMID 27780334, PMID 31577867, PMID 31818787, PMID 34510411, PMID 34817851, PMID 36708956, PMID 23485955, PMID 23497790, PMID 26644957, PMID 27685842, PMID 30508090, PMID 32860422, PMID 34235612, PMID 37656180, PMID 39428602, PMID 21731833, PMID 22106941, PMID 23106023, PMID 23216998, PMID 23585997, PMID 23585999, PMID 23673347, PMID 24127687, PMID 24766999, PMID 27035159, PMID 29523415, PMID 33128208, PMID 34894307, PMID 35022754, PMID 37099968, PMID 38421922, PMID 38557430, PMID 40607746, PMID 40852147, PMID 41055581, PMID 15748841, PMID 16248986, PMID 18832427, PMID 20816039, PMID 22027845
2008 (12), 2014 (8), 2018 (7), 2019 (3), 2023 (3), 2025 (3), 2009 (2), 2015 (2), 2016 (2), R01MH121632 (2), 2017 (1), I01RD001520 (1), R01AT000001 (1), R01DA023190 (1), R01MD005905 (1)